Targeted therapy for ALK-positive histiocytosis masquerading as optic nerve tumor: a case report
Child's Nervous System · 09.03.2026 · 42 (1)
DOI: 10.1007/s00381-026-07189-w ↗Kurz gefasst
Fallbericht in der Zeitschrift Child's Nervous System, online erschienen am 09.03.2026. Verfasst von Debajyoti Datta und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Neurosurgery, Children's Hospital of Eastern Ontario (CHEO), 401 Smyth Rd, Ottawa, Ontario, K1H 8L1, Canada. deb.d1988@gmail.co…. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Histiocytosis, Optic Nerve Neoplasms. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
ALK-positive histiocytosis is a recently described histiocytic neoplasm characterized by ALK immunoreactivity in CD163-positive histiocytes and has been shown to respond favorably to ALK inhibitors. ALK-positive histiocytosis is a clonal neoplastic disorder that can manifest as single-system or multisystem disease, with frequent neurological involvement. Reported gene fusions include KIF5B-ALK, TPM3-ALK, and others, leading to constitutive activation of downstream signaling pathways such as MAPK and PI3K/AKT/mTOR. Although surgical resection and conventional chemotherapy have been used, ALK inhibitors offer a targeted and effective therapeutic option, particularly for intracranial disease. We report a case of a 17-month-old boy presenting with left eye deviation, ptosis, and visual loss. Magnetic resonance imaging revealed a lobulated, contrast-enhancing mass involving the orbital and canalicular segments of the left optic nerve, extending into the cavernous sinus, with additional enhancing foci in the left frontal and pineal regions. Given the atypical radiological features, surgical biopsy was performed and demonstrated ALK-positive histiocytosis with KIF5B-ALK gene fusion. Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, was started which showed significant disease regression at 18-month follow-up. This report highlights the favorable response to targeted ALK inhibition in central nervous system ALK-positive histiocytosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Neurosurgery, Children's Hospital of Eastern Ontario (CHEO), 401 Smyth Rd, Ottawa, Ontario, K1H 8L1, Canada. deb.d1988@gmail.com.
- University of Ottawa, Ottawa, Ontario, Canada. deb.d1988@gmail.com.
- Division of Pediatric Neurosurgery, Children's Hospital of Eastern Ontario (CHEO), 401 Smyth Rd, Ottawa, Ontario, K1H 8L1, Canada.
- University of Ottawa, Ottawa, Ontario, Canada.
Zitieren
APA
Datta, D., & Nzau, M. (2026). Targeted therapy for ALK-positive histiocytosis masquerading as optic nerve tumor: a case report. Child's Nervous System, 42(1). https://doi.org/10.1007/s00381-026-07189-w
Vancouver
Datta D, Nzau M. Targeted therapy for ALK-positive histiocytosis masquerading as optic nerve tumor: a case report. Child's Nervous System. 2026;42(1). doi:10.1007/s00381-026-07189-w
BibTeX
@article{Datta2026,
author = {Datta, Debajyoti and Nzau, Munyao},
title = {Targeted therapy for ALK-positive histiocytosis masquerading as optic nerve tumor: a case report},
journal = {Child's Nervous System},
year = {2026},
volume = {42},
number = {1},
doi = {10.1007/s00381-026-07189-w}
}
EUVIMED